Ginkgo Bioworks
DNA
278 hedge funds and large institutions have $2.74B invested in Ginkgo Bioworks in 2022 Q3 according to their latest regulatory filings, with 59 funds opening new positions, 100 increasing their positions, 56 reducing their positions, and 38 closing their positions.
81% more call options, than puts
Call options by funds: $35.3M | Put options by funds: $19.5M
79% more repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 56
55% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 38
42% more capital invested
Capital invested by funds: $1.93B → $2.74B (+$810M)
7% more funds holding
Funds holding: 260 → 278 (+18)
0.04% more ownership
Funds ownership: 1.8% → 1.84% (+0.04%)
50% less funds holding in top 10
Funds holding in top 10: 8 → 4 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$223M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$118M |
| 3 |
Morgan Stanley
New York
|
+$44.8M |
| 4 |
NAMA
Nikko Asset Management Americas
New York
|
+$27.2M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$27.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GA
General Atlantic
New York
|
-$111M |
| 2 |
SIG
Senator Investment Group
New York
|
-$22.9M |
| 3 |
Coatue Management
New York
|
-$18.9M |
| 4 |
Goldman Sachs
New York
|
-$9.4M |
| 5 |
Millennium Management
New York
|
-$8.79M |
DNA Hedge Fund Activity: Q3 2022 in Review
278 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks (DNA) for Q3 2022, worth a combined $2.74B — up 42% from $1.93B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new DNA positions and 38 closed out — a net gain of 21 holders — while 100 added to existing stakes and 56 trimmed.
The largest buyer was Viking Global Investors, adding an estimated $223M. The largest seller was General Atlantic, cutting an estimated $111M.
- 278 institutional investors held Ginkgo Bioworks (DNA) as of Q3 2022, up from 260 in Q2 2022.
- Funds reported $2.74B of Ginkgo Bioworks stock for Q3 2022, up 42% quarter-over-quarter.
- 59 funds opened new Ginkgo Bioworks positions in Q3 2022 and 38 closed out, a net change of +21 holders.
- The largest Ginkgo Bioworks buyer in Q3 2022 was Viking Global Investors, an estimated $223M added.
- The largest Ginkgo Bioworks seller in Q3 2022 was General Atlantic, an estimated $111M sold.
Based on aggregated 13F filings for Q3 2022.